South Wales, April 6 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "CTX611" on March 16. The details about the trademark application no. UK00004355478 published in the journal no. 2026/014 (April 3).
With HGF Limited as representative, CRISPR Therapeutics AG filed the trademark application for the below mentioned good(s)/service(s).
Class 5 : Cells for medical or clinical use in the field of gene therapy for the treatment of cardiovascular diseases and thromboembolic diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy.
Class 42 : Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of gene therapy.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004355478
Disclaimer: Curated by HT Syndication.
